What does GPCR stand for?

GPCR stands for G-Protein-Coupled Receptor. The receptors are also called seven-transmembrane (7TM) receptors, serpentine receptors, or heptahelical receptors, all referring to the seven-helix architecture in the cell membrane.

How many GPCRs are in the human genome?

Approximately 800 distinct GPCRs are encoded, of which roughly half are olfactory receptors involved in the sense of smell.

Are opioid receptors GPCRs?

Yes. All four classical opioid receptor subtypes - mu (MOR), delta (DOR), kappa (KOR), and nociceptin (NOP) - are GPCRs that couple primarily to inhibitory Gαi/o G-proteins.

What is the difference between G-protein and β-arrestin signaling?

G-protein signaling and β-arrestin recruitment are two parallel downstream consequences of GPCR activation. G-protein signaling typically mediates the rapid effector responses; β-arrestin recruitment typically mediates desensitization, internalization, and an alternative cascade. Biased agonism describes ligands that preferentially activate one of these routes over the other.

What does 'seven-transmembrane' mean?

It refers to the GPCR's seven alpha-helices that traverse the cell membrane, connected by extracellular and intracellular loops. The structure is conserved across all GPCRs.

What fraction of medications target GPCRs?

Approximately 30-35% of FDA-approved pharmaceuticals target G-protein-coupled receptors, making the family the single most important drug-target class in modern medicine.

Receptor Pharmacology

G-Protein-Coupled Receptor (GPCR)

At-a-glance comparison

Spec	Value
Other names	Seven-transmembrane (7TM) receptor; serpentine receptor; heptahelical receptor
Number in human genome	Approximately 800 GPCRs (including ~400 olfactory receptors)
Defining structural feature	Seven transmembrane alpha-helices traversing the cell membrane
Primary signaling	Activation of heterotrimeric G-proteins (Gαs, Gαi/o, Gαq, Gα12/13)
Alternative signaling	β-arrestin recruitment leading to receptor desensitization and alternative downstream cascades
GPCR families relevant to kratom alkaloids	Opioid receptors (MOR, DOR, KOR, NOP); alpha-2 adrenergic; serotonin receptor subtypes
Fraction of FDA-approved drugs targeting GPCRs	Estimated at 30-35%

What is a GPCR?

A G-protein-coupled receptor is a transmembrane protein with a characteristic seven-helix architecture: seven hydrophobic alpha-helices embedded in the cell membrane, connected by alternating intracellular and extracellular loops, with the amino-terminus on the extracellular side and the carboxy-terminus on the intracellular side. This architecture defines the superfamily.

GPCRs constitute the largest receptor family in the human genome - approximately 800 distinct receptors, of which roughly half are olfactory receptors involved in smell. The remaining several hundred include receptors for hormones, neurotransmitters, and many other endogenous signaling molecules. Approximately 30-35% of FDA-approved pharmaceuticals target GPCRs, making the family the single most important drug-target class in medicine.

How GPCRs signal

When an agonist binds the extracellular face of a GPCR, the receptor undergoes a conformational change that activates intracellular heterotrimeric G-proteins (composed of Gα, Gβ, and Gγ subunits). The G-protein then dissociates and the Gα subunit modulates downstream effectors such as adenylate cyclase, phospholipase C, or ion channels, depending on which Gα subtype is engaged. The four major Gα subtype families are Gαs (stimulates adenylate cyclase), Gαi/o (inhibits adenylate cyclase), Gαq (activates phospholipase C), and Gα12/13.

After activation, GPCRs are typically phosphorylated by GPCR kinases, which recruits β-arrestin to the receptor. β-Arrestin mediates receptor desensitization (uncoupling from the G-protein), receptor internalization (endocytosis from the cell surface), and a distinct cascade of alternative downstream signaling. The relative balance between G-protein and β-arrestin signaling at any given receptor is the foundation of biased agonism.

Opioid receptors as GPCRs

All four classical opioid receptor subtypes - MOR, DOR, KOR, and NOP - are GPCRs that couple primarily to inhibitory Gαi/o G-proteins. The mu-opioid receptor is the principal molecular target of clinically used opioid analgesics and the principal in vitro target of the kratom alkaloids mitragynine and 7-hydroxymitragynine. Both alkaloids activate MOR with G-protein-biased signaling, meaning they preferentially activate G-protein-mediated downstream pathways over β-arrestin recruitment in receptor-functional assays.

Common questions about g-protein-coupled receptor (gpcr)

What does GPCR stand for?: GPCR stands for G-Protein-Coupled Receptor. The receptors are also called seven-transmembrane (7TM) receptors, serpentine receptors, or heptahelical receptors, all referring to the seven-helix architecture in the cell membrane.
How many GPCRs are in the human genome?: Approximately 800 distinct GPCRs are encoded, of which roughly half are olfactory receptors involved in the sense of smell.
Are opioid receptors GPCRs?: Yes. All four classical opioid receptor subtypes - mu (MOR), delta (DOR), kappa (KOR), and nociceptin (NOP) - are GPCRs that couple primarily to inhibitory Gαi/o G-proteins.
What is the difference between G-protein and β-arrestin signaling?: G-protein signaling and β-arrestin recruitment are two parallel downstream consequences of GPCR activation. G-protein signaling typically mediates the rapid effector responses; β-arrestin recruitment typically mediates desensitization, internalization, and an alternative cascade. Biased agonism describes ligands that preferentially activate one of these routes over the other.
What does 'seven-transmembrane' mean?: It refers to the GPCR's seven alpha-helices that traverse the cell membrane, connected by extracellular and intracellular loops. The structure is conserved across all GPCRs.
What fraction of medications target GPCRs?: Approximately 30-35% of FDA-approved pharmaceuticals target G-protein-coupled receptors, making the family the single most important drug-target class in modern medicine.

References

Hauser AS, Attwood MM, Rask-Andersen M, et al. (2017). Trends in GPCR drug discovery: new agents, targets and indications. Nature Reviews Drug Discovery.
Pierce KL, Premont RT, Lefkowitz RJ. (2002). Seven-transmembrane receptors. Nature Reviews Molecular Cell Biology.
Manglik A, et al. (2016). Structure-based discovery of opioid analgesics with reduced side effects. Nature.
Kenakin T. (2019). Biased receptor signaling in drug discovery. Pharmacological Reviews.
International Union of Basic and Clinical Pharmacology. https://www.guidetopharmacology.org

Important safety information:

Products containing 7-hydroxymitragynine (7-OH) are sold for adult use only (21+). These statements have not been evaluated by the U.S. Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease. The FDA has raised safety concerns regarding concentrated 7-OH products; consult a qualified healthcare professional before use. Do not operate vehicles or machinery after use. Keep out of reach of children and pets. Laws vary by state, buyers are responsible for knowing applicable law.